The safety and tolerability of COMP360 in participants with post-traumatic stress disorder (PTSD).
Topic PTSD
Compound Psilocybin
Country United Kingdom
Visit trial
Status
Recruiting
Start date
11 April 2022
End date
21 August 2023
Chance of happening
89%
Phase
Phase II
Design
Open
Type
Interventional
Generation
Second
Participants
29
Sex
All
Age
18- 99
Therapy
No
Trial Details
The safety and tolerability of COMP360 in participants with post-traumatic stress disorder (PTSD).NCT Number NCT05312151
Sponsors & Collaborators
COMPASS PathwaysCOMPASS Pathways is a publicly listed company (NASDAQ) that aims to develop psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. It has gone public and has received substantial investment from atai.
King's College London
KCL is home to the Psychedleic Trials Group.
Measures Used
Clinician-Administered PTSD Scale for DSM-5The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is often considered the gold standard in PTSD assessment. The 30-item structured interview was developed by staff at the U.S. Department of Veterans Affairs National Centre for PTSD. CAPS can be used to make a current diagnosis, lifetime diagnosis or assess PTSD symptoms over the past week in accordance with DSM-5 criteria.